Pfiz­er wants you. And you. And you. And you.

Pfiz­er ex­ecs turned up at J.P. Mor­gan with a sim­ple mes­sage: We’re not done do­ing deals.

Pfiz­er CFO Frank D’Ame­lio said they’re on the look­out for new deals that will grow rev­enue “now or soon,” but frankly are still in­ter­est­ed in ear­ly-stage ef­forts as well.

That might not be sur­pris­ing, but the phar­ma gi­ant has been blaz­ing a wide path in the mar­ket over the past two years. Af­ter failed at­tempts to pull off a ma­jor over­haul with a re­al­ly big M&A deal like an As­traZeneca or Al­ler­gan buy­out — de­railed by the Oba­ma ad­min­is­tra­tion’s back­lash against tax in­ver­sions — Pfiz­er shook things up with a $14 bil­lion deal to buy Medi­va­tion, which pro­vid­ed a prod­uct as well as a late-stage drug can­di­date.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.